FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: ValueSet/2.16.840.1.113762.1.4.1196.495

Packageus.nlm.vsac
Resource TypeValueSet
Id2.16.840.1.113762.1.4.1196.495
FHIR VersionR4
Sourcehttp://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1196.495/expansion
URLhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495
Version20210909
Statusactive
Date2021-09-09T01:01:05-04:00
NameICSLABALAMAPreparations
TitleICS LABA LAMA Preparations
Realmus
Authorityhl7
Purpose(Clinical Focus: This valueset contains oral inhaled corticosteroid preparations in combination with a long-acting beta agonist and a long-acting muscarinic antagonist that may be used for maintenance controller therapy in adult asthmatics. As of Sept 2020, the oral inhalant combination of fluticasone furoate + umeclidinium + vilanterol is indicated for the maintenance treatment of asthma in patients aged 18 years and older.),(Data Element Scope: FHIR MedicationStatement.medicationCodeableConcept, MedicationRequest.medicationCodeableConcept),(Inclusion Criteria: Includes fluticasone/umeclidinium/vilanterol oral inhalation preparations),(Exclusion Criteria: none)

Resources that use this resource

No resources found


Resources that this resource uses

CodeSystem
rxnormRxNorm

Narrative

No narrative content found in resource


Source

{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1196.495",
  "meta": {
    "versionId": "16",
    "lastUpdated": "2023-12-21T17:43:03.000-05:00",
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail": {
        "name": "Elimu Informatics Author"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate": "2025-03-03"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate": "2021-09-09"
    }
  ],
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495",
  "identifier": [
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113762.1.4.1196.495"
    }
  ],
  "version": "20210909",
  "name": "ICSLABALAMAPreparations",
  "title": "ICS LABA LAMA Preparations",
  "status": "active",
  "experimental": false,
  "date": "2021-09-09T01:01:05-04:00",
  "publisher": "NHLBI Implementation Science and Health Care Innovation Steward",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "US"
        }
      ]
    }
  ],
  "purpose": "(Clinical Focus: This valueset contains oral inhaled corticosteroid preparations in combination with a long-acting beta agonist and a long-acting muscarinic antagonist that may be used for maintenance controller therapy in adult asthmatics.  As of Sept 2020, the oral inhalant combination of fluticasone furoate + umeclidinium + vilanterol is indicated for the maintenance treatment of asthma in patients aged 18 years and older.),(Data Element Scope: FHIR \nMedicationStatement.medicationCodeableConcept, MedicationRequest.medicationCodeableConcept),(Inclusion Criteria: Includes fluticasone/umeclidinium/vilanterol oral inhalation preparations),(Exclusion Criteria: none)",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept": [
          {
            "code": "1945039",
            "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler"
          },
          {
            "code": "1945044",
            "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]"
          },
          {
            "code": "1945047",
            "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler"
          },
          {
            "code": "1945048",
            "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]"
          }
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:c37db04e-d713-4f93-b185-7c9489baf734",
    "timestamp": "2025-05-23T19:13:52-04:00",
    "total": 4,
    "contains": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1945039",
        "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1945044",
        "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1945047",
        "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1945048",
        "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]"
      }
    ]
  }
}